Drug intelligence / Profile preview

mHSP65-TTL

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

**mHSP65-TTL** is an experimental, preclinical therapeutic cancer vaccine composed of recombinant mycobacterial heat shock protein 65 and tumor tissue lysate prepared from Panc02 pancreatic cancer tissue. In a C57BL/6 mouse Panc02 pancreatic cancer model, vaccination prolonged survival; low-dose cyclophosphamide enhanced this antitumor effect. The reported immune effects included increased splenic expression of RORγt and interleukin-17A transcripts following vaccination, supporting immune activation directed at tumor-associated antigens present in the lysate.

Other names: mHSP65 + TTLmHSP65-TTL vaccinemHSP-65-TTL vaccinemHSP 65-TTL vaccineMHSP65-TTLMHSP-65-TTLMHSP 65-TTL

Beyond the preview

Go deeper on mHSP65-TTL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mHSP65-TTL.

Explore the full profile